Search Within

Robert Motzer

  1. "Radiochemistry and Imaging Sciences Service"
Formats
  1. Meeting Abstract (3)
Groups
  1. Department of Medicine (3)
  2. GSK Faculty (3)
  3. Genitourinary Oncology Service (3)
  4. Molecular Imaging and Therapy Service (3)
  5. Molecular Pharmacology and Chemistry Program Faculty (3)
  6. Radiochemistry and Imaging Sciences Service (3)

More Groups

People
  1. Andrea Knezevic (3)
  2. Darren Feldman (3)
  3. Hijin Park (3)
  4. Martin Voss (3)
  5. Neeta Pandit-Taskar (3)
  6. Serge Lyashchenko (3)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (1)
Publications
  1. Journal of Clinical Oncology (3)
Publishers
  1. American Society of Clinical Oncology (3)

Results (3)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save